Breaking News Instant updates and real-time market news.

A

Agilent

$88.02

0.565 (0.65%)

, AGE

A.G. Edwards

$1.85

0.13 (7.56%)

04:55
01/15/20
01/15
04:55
01/15/20
04:55

EBDF Group to hold a conference

Biotech Showcase 2020 will be held in San Francisco on January 13-15.

A

Agilent

$88.02

0.565 (0.65%)

AGE

A.G. Edwards

$1.85

0.13 (7.56%)

ALNY

Alnylam

$118.48

3.68 (3.21%)

AZN

AstraZeneca

$50.18

0.5 (1.01%)

BAYRY

Bayer

$0.00

(0.00%)

BCLI

BrainStorm

$4.34

-0.04 (-0.91%)

ENTX

Entera Bio

$2.78

-0.03 (-1.07%)

DYAI

Dyadic International

$5.50

-0.135 (-2.40%)

DTIL

Precision BioSciences

$13.40

-0.12 (-0.89%)

DD

DuPont

$60.16

-0.25 (-0.41%)

CYCC

Cyclacel Pharmaceuticals

$0.74

-0.0549 (-6.91%)

CTLT

Catalent

$60.34

0.88 (1.48%)

COWN

Cowen Group

$16.34

-0.2 (-1.21%)

GMAB

Genmab

$22.44

-0.21 (-0.93%)

IDXG

Interpace Biosciences

$0.62

(0.00%)

LCTX

Lineage Cell Therapeutics

$0.75

-0.0146 (-1.92%)

PHIO

Phio Pharmaceuticals

$0.20

0.0117 (6.35%)

PJC

Piper Jaffray

$0.00

(0.00%)

TNXP

Tonix Pharmaceuticals

$1.48

0.03 (2.07%)

TROV

Trovagene

$1.47

0.15 (11.41%)

VCYT

Veracyte

$28.58

0.17 (0.60%)

VIE

Viela Bio

$37.10

4.17 (12.66%)

PSTV

Plus Therapeutics

$2.81

0.02 (0.72%)

RDUS

Radius Health

$20.14

1.77 (9.64%)

MRNA

Moderna

$20.01

-0.21 (-1.04%)

MRK

Merck

$89.93

0.5 (0.56%)

NAVB

Navidea

$1.49

-0.03 (-1.97%)

NBSE

NeuBase Therapeutics

$6.31

-0.19 (-2.92%)

NVO

Novo Nordisk

$59.62

0.66 (1.12%)

NVS

Novartis

$94.47

0.765 (0.82%)

OVID

Ovid Therapeutics

$3.59

0.09 (2.57%)

STI

Merged to become TFC

$0.00

(0.00%)

XON

Intrexon

$7.20

0.46 (6.82%)

SLRX

Salarius Pharmaceuticals

$3.20

0.15 (4.92%)

VVUS

VIVUS

$2.72

-0.01 (-0.37%)

SIVB

SVB Financial

$253.42

-0.36 (-0.14%)

VRML

Vermillion

$0.79

-0.0453 (-5.39%)

VKTX

Viking Therapeutics

$7.36

0.045 (0.62%)

  • 15

    Jan

  • 15

    Jan

  • 16

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 04

    Feb

  • 05

    Feb

  • 06

    Feb

  • 10

    Feb

  • 12

    Feb

  • 13

    Feb

  • 18

    Feb

  • 24

    Feb

  • 26

    Feb

  • 12

    Mar

  • 14

    Mar

  • 26

    Mar

A Agilent
$88.02

0.565 (0.65%)

01/06/20
SBSH
01/06/20
INITIATION
Target $85
SBSH
Neutral
Agilent initiated with a Neutral at Citi
Citi analyst Patrick Donnelly initiated coverage of Agilent with a Neutral rating and $85 price target.
11/26/19
JPMS
11/26/19
NO CHANGE
Target $90
JPMS
Overweight
Agilent price target raised to $90 from $85 at JPMorgan
JPMorgan analyst Tycho Peterson raised his price target for Agilent Technologies to $90 from $85 saying the company reported a "healthy beat" for fiscal Q4. Further, its initial fiscal 2020 guidance "looks typically conservative," says the analyst, who keeps an Overweight rating on the shares.
01/07/20
WELS
01/07/20
INITIATION
WELS
Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector
Wells Fargo analyst Dan Leonard initiated coverage of the Life Science Tools, Services, and Diagnostics Sector in a research note titled "Tools, Services Have Evolved to Better Place but Stay Selective." Leonard said the sectors have "greater secular growth than 5+ years ago, with more exposure to Biopharma and China, and less cyclicality." While the analyst noted the industry has changed for the better, he advocated for being selective, citing elevated relative valuations due to the market recognizing these positives, and decelerating growth. The analyst initiated Agilent (A), Avantor (AVTR), Bio-Rad (BIO), Bruker (BRKR), Danaher (DHR), and Charles River (CRL) with Overweight ratings, noting they were all volatile, and initiated Iqvia (IQV) and LabCorp (LH) with Overweight ratings. The analyst initiated Quest Diagnostics (DGX) and Illumina (ILMN) with Underweight ratings, noting they were both volatile, and also initiated Waters (WAT) with an Underweight rating.
01/07/20
WELS
01/07/20
INITIATION
Target $100
WELS
Overweight
Agilent initiated with an Overweight at Wells Fargo
Wells Fargo analyst Dan Leonard initiated coverage of Agilent with an Overweight rating and $100 price target.
AGE A.G. Edwards
$1.85

0.13 (7.56%)

ALNY Alnylam
$118.48

3.68 (3.21%)

11/25/19
STFL
11/25/19
NO CHANGE
Target $136
STFL
Buy
Alnylam one of few mid-caps with 'plausible large-cap aspirations,' says Stifel
Stifel analyst Paul Matteis raised his price target on Alnylam shares to $136 from $126 citing earlier than expected Givosiran approval, higher than anticipated pricing and "promising advancements" in the company's early stage pipeline. A major theme of the company's analyst day was Alnylam's confidence in pursuing larger, non-orphan indications, said Matteis, who also noted that 2019 "was framed as a peak operating loss year" although no guidance was given during the event. The analyst, who sees a "compelling case" for Alnylam being "one of the few mid-caps with plausible large-cap aspirations," keeps a Buy rating on the stock.
11/25/19
BMOC
11/25/19
NO CHANGE
Target $143
BMOC
Outperform
Alnylam price target raised to $143 from $138 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Alnylam to $143 and kept his Buy rating after its R&D Day highlighted the company's commercial and pipeline plans. With Lumasiran Phase 3 trial data expected next month and his estimated "likely approval" for the drug in late-2020, the analyst also adds its projected revenue to his model, assigning an 80% probability-of-success to the program while also citing Alnylam's global Onpattro expansion driving further top-line growth.
12/17/19
PIPR
12/17/19
NO CHANGE
Target $155
PIPR
Overweight
Alnylam price target raised to $155 from $145 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff maintained an Overweight rating on Alnylam Pharmaceuticals and raised his price target on the shares to $155 from $145 after the company reported "positive" Phase III ILLUMINATE-A data on lumasiran in primary hyperoxaluria type 1. Tenthoff said he is "confident" in the treatment getting approval in the U.S. by year end 2020 and in Europe in 2021 and he forecasts lumasirin sales of $8M in 2020 and $85M in 2021. The analyst also noted that ONPATTRO and GIVLAARI launches are "progressing" to drive 2020 sales.
12/18/19
CANT
12/18/19
NO CHANGE
Target $176
CANT
Overweight
Alnylam price target raised to $176 from $159 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Alnylam Pharmaceuticals to $176 from $159 saying the company reported a "very clean" positive top-line readout for lumasiran. The analyst finds it notable that lumasiran is the company's fourth pivotal RNAi readout in the past two years and will be the third wholly owned commercial product after Onpattro and recently approved Givlaari. She thinks the positive update adds to Alnylam's recent momentum heading into 2020, as its "rapid transition to a full fledged commercial company with a robust pipeline continues." Young reiterates an Overweight rating on Alnylam.
AZN AstraZeneca
$50.18

0.5 (1.01%)

01/13/20
ROTH
01/13/20
NO CHANGE
ROTH
Amarin's Vascepa now the 'go-to' after competitor failures, says Roth Capital
Roth Capital analyst Yasmeen Rahimi maintained a Buy rating and $31 price target on Amarin (AMRN) following the failures of two competitors to Amarin's Vascepa -- those being the discontinuation of AstraZeneca's (AZN) Epanova trial and the negative TRIOLOGY 1 data from Acasti Pharma's (ACST) CaPre -- which leaves Vascepa as the "'go-to' omega-3 product" and kills the central bear case against Amarin.
12/26/19
STFL
12/26/19
NO CHANGE
Target $180
STFL
Buy
Stifel sees path to $230 for Iqvia shares after 'significant' AstraZeneca win
Stifel analyst Shlomo Rosenbaum views AstraZeneca (AZN) selecting the Orchestrated Customer Engagement platform as a "significant win" for Iqvia Holdings (IQV). The deal is a takeaway from Veeva (VEEV), is for all of AstraZeneca in the U.S., and has the potential for upsizing both through global expansion and additional modules, Rosenbaum tells investors in a research note. The analyst continues to like the Iqvia story and sees a valuation path in the $230s range in the next several years as the story plays out. Iqvia closed Tuesday down 17c to $154.70. Rosenbaum has a Buy rating on the name with a $180 price target.
01/13/20
STFL
01/13/20
NO CHANGE
Target $28
STFL
Hold
Amarin should rally on failure of two potential competitors, says Stifel
Stifel analyst Derek Archila expects shares of Amarin (AMRN) to be up today on news that AstraZeneca (AZN) discontinued Epanova's STRENGTH cardiovascular outcomes trial given the low likelihood it would demonstrate a cardiovascular benefit. While the STRENGTH study had a low probability of a positive outcome, its failure "no doubt reinforces the importance" of the pure eicosapentaenoic acid hypothesis and Vascepa's REDUCE-IT results, Archila tells investors in a research note. In addition, Acasti Pharma (ACST) reported that its Phase 3 TRILOGY 1 study results for its lead candidate, CaPre, in patients with hypertriglyceridemia failed, Archila points out. He notes that this program was also viewed as a potential competitor to Amarin's Vascepa. The analyst believes that with both of these failures, investor fears over near-to-medium term branded competition to Vaspeca should subside. Archila has a Hold rating on Amarin with a $28 price target. The stock in premarket trading is up 6% to $20.05.
01/13/20
JPMS
01/13/20
NO CHANGE
JPMS
Epanova discontinuation positive for Amarin, says JPMorgan
JPMorgan analyst Jessica Fye views the removal of Epanova as a positive for Amarin (AMRN). AstraZeneca (AZN) said this morning that it is closing the Phase III trial for Epanova in mixed dyslipidaemia following the recommendation from an independent Data Monitoring Committee. Epanova is an omega-3 carboxylic acid and was being studied to demonstrate a possible benefit in patients with mixed dyslipidaemia who are at increased risk of cardiovascular disease. Shares of Amarin are up 6%, or $1.07, to $20.02 in premarket trading.
BAYRY Bayer
$0.00

(0.00%)

12/17/19
BREN
12/17/19
UPGRADE
Target $86
BREN
Buy
Bayer upgraded to Buy from Hold at Berenberg
Berenberg analyst Sebastian Bray upgraded Bayer to Buy from Hold with a EUR 86 price target, up from EUR 75. The company's earnings growth is among the fastest in the space in the near-term, and corn and soybean prices are unlikely to drop further, Bray tells investors in a research note. Further, two court cases have been delayed, and a settlement could occur in the first half next year, adds the analyst.
10/21/19
PIPR
10/21/19
NO CHANGE
Target $100
PIPR
Overweight
Piper reiterates Overweight on Crispr Therapeutics with $100 price target
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Crispr Therapeutics (CRSP) with a $100 price target after the company announced the consolidation of the Casebia joint venture with Bayer (BAYRY). Casebia will now operate within Crispr to develop its hemophilia, ophthalmology and autoimmune programs, Tenthoff tells investors in a research note. The primary driver for shares remains first ever CTX001 data in beta thalassemia and sickle cell disease in December, says Tenthoff.
12/19/19
BOFA
12/19/19
UPGRADE
BOFA
Buy
Elanco upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Michael Ryskin upgraded Elanco (ELAN) to Buy from Neutral. The analyst notes that while other animal health companies like Zoetis (ZTS) and IDEXX (IDXX) outperformed the S&P500, Elanco suffered with an 11% year-to-date decline on broadly negative initial one-off reaction to the Bayer animal health business acquisition.
12/17/19
BREN
12/17/19
UPGRADE
Target $86
BREN
Buy
Bayer upgraded to Buy from Hold at Berenberg
Berenberg analyst Sebastian Bray upgraded Bayer to Buy from Hold with a EUR 86 price target, up from EUR 75. The company's earnings growth is among the fastest in the space in the near-term, and corn and soybean prices are unlikely to drop further, Bray tells investors in a research note. Further, two court cases have been delayed, and a settlement could occur in the first half next year, adds the analyst.
BCLI BrainStorm
$4.34

-0.04 (-0.91%)

ENTX Entera Bio
$2.78

-0.03 (-1.07%)

DYAI Dyadic International
$5.50

-0.135 (-2.40%)

10/16/19
DAWS
10/16/19
INITIATION
Target $14
DAWS
Buy
Dyadic International initiated with a Buy at Dawson James
Dawson James started Dyadic International with a Buy rating and $14 price target.
DTIL Precision BioSciences
$13.40

-0.12 (-0.89%)

08/09/19
BTIG
08/09/19
INITIATION
BTIG
Buy
Precision BioSciences initiated with a Buy at BTIG
08/09/19
BTIG
08/09/19
INITIATION
Target $22
BTIG
Buy
Precision BioSciences initiated with a Buy at BTIG
BTIG analyst Amanda Murphy initiated Precision BioSciences with a Buy rating and a price target of $22 as part of her broader research note on CAR-T cell therapy names developing "off-the-shelf" engineered cell therapeutics for oncology. The analyst is positive on the company's pipeline of allogeneic CAR-T product candidates and its "novel ARCUS genome editing platform" giving it the opportunity to develop additional candidates in high value areas.
04/22/19
JEFF
04/22/19
INITIATION
Target $25
JEFF
Buy
Precision BioSciences initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft started Precision BioSciences with a Buy rating and $25 price target. The analyst believes the company's proprietary gene-editing technology and platform should provide long-term value.
09/16/19
HCWC
09/16/19
NO CHANGE
Target $21
HCWC
Buy
Precision IND accepted a quarter sooner than expected, says H.C. Wainwright
After Precision BioSciences announced the FDA has accepted its Investigational New Drug application for PBCAR20A, the company's second off-the-shelf chimeric antigen receptor T cell therapy program, H.C. Wainwright analyst Debjit Chattopadhyay said the PBCAR20A IND came about a quarter ahead of his expectation. He expects a potentially expedited dose escalation segment of its trial, with a likely data readout during the second half of next year, said Chattopadhyay, who keeps a Buy rating and $21 price target on Precision shares.
DD DuPont
$60.16

-0.25 (-0.41%)

01/14/20
01/14/20
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CyberArk (CYBR) initiated with a Neutral at DA Davidson. 2. ConocoPhillips (COP) initiated with a Positive at Susquehanna. 3. DuPont (DD) initiated with a Buy at Gordon Haskett. 4. Valero (VLO) initiated with an Overweight at Barclays. 5. GDS Holdings (GDS) initiated with an Outperform at Macquarie. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/08/20
SPIN
01/08/20
UPGRADE
SPIN
Buy
DuPont upgraded to Buy from Hold at Spin-Off Research
Spin-Off Research upgraded DuPont to Buy from Hold.
01/14/20
BMOC
01/14/20
NO CHANGE
Target $82
BMOC
Outperform
DuPont price target lowered to $82 from $87 at BMO Capital
BMO Capital analyst John McNulty lowered his price target on DuPont to $82 to reflect a "more difficult macro backdrop" as well as 25c in one-time earnings per share benefits from 2019 that will not be seen this year. The analyst still keeps his Outperform rating on the stock given the company's "industry-leading platforms" with ties to secular themes that should help DuPont grow at better-than-GDP rates and at margins exceeding the majority of specialty chemical and industrial companies.
01/14/20
GDHS
01/14/20
INITIATION
Target $71
GDHS
Buy
DuPont initiated with a Buy at Gordon Haskett
Gordon Haskett analyst John Inch initiated coverage of DuPont (DD) with a Buy rating and $71 price target. DuPont shares have underperformed but he believes a turn could be at hand as he thinks the N&B deal with IFF (IFF) unlocks significant value and still expects that DuPont can realize additional structural margin improvements across its portfolio. In terms of PFAS, Inch thinks the issue isn't likely to go away, but he believes Chemours (CC) "would have to effectively go bankrupt before DuPont would find itself significantly on the financial hook for material PFAS costs."
CYCC Cyclacel Pharmaceuticals
$0.74

-0.0549 (-6.91%)

CTLT Catalent
$60.34

0.88 (1.48%)

10/17/19
SPHN
10/17/19
INITIATION
Target $56
SPHN
Overweight
Catalent resumed with an Overweight at Stephens
Stephens analyst Jacob Johnson resumed coverage of Catalent with an Overweight rating and $56 price target. While the stock's valuation is relatively elevated on a historical basis, he thinks the premium is warranted given the growth prospects for the company's biologics and cell/gene therapy assets.
08/28/19
08/28/19
DOWNGRADE

Sector Weight
Catalent downgraded to Sector Weight on valuation at KeyBanc
As previously reported, KeyBanc analyst Donald Hooker downgraded Catalent to Sector Weight from Overweight on valuation, with shares now at near all-time highs. The analyst believes free cash flow will be limited at 20%-30% of EBITDA due to heavy capital spending, and the company will be carrying a high debt ratio, both of which may limit flexibility.
08/28/19
BARD
08/28/19
NO CHANGE
Target $60
BARD
Outperform
Catalent price target raised to $60 from $50 at Baird
Baird analyst Evan Stover raised his price target on Catalent to $60 from $50 citing recent smaller challenges fading, Paragon and broader Biologics update was solid, and the company is accelerating toward its EBITDA growth goal. Stover reiterated his Outperform rating on Catalent shares.
08/28/19
08/28/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Autodesk (ADSK) downgraded to Underperform from Neutral at BofA/Merrill with analyst Kash Rangan saying while the company posted solid July quarter results, uncertainty has increased as its fiscal 2020 guidance was lowered across the board. 2. Antero Midstream (AM) downgraded to Market Perform from Outperform at Raymond James. 3. Catalent (CTLT) downgraded to Sector Weight from Overweight at KeyBanc with analyst Donald Hooker saying he believes free cash flow will be limited at 20%-30% of EBITDA due to heavy capital spending, and the company will be carrying a high debt ratio, both of which may limit flexibility. 4. Kelly Services (KELYA) downgraded to Neutral from Buy at Northcoast with analyst John Healy saying shares are approaching his liquidation value of around $26. 5. Nabors Industries (NBR), Nine Energy Services (NINE), and Quintana Energy Services (QES) downgraded to Neutral from Buy at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
COWN Cowen Group
$16.34

-0.2 (-1.21%)

07/23/19
BUCK
07/23/19
INITIATION
BUCK
Buy
Cowen Group initiated with a Buy at Buckingham
GMAB Genmab
$22.44

-0.21 (-0.93%)

01/02/20
GUGG
01/02/20
DOWNGRADE
GUGG
Neutral
Incyte downgraded to Neutral after strong 2019 at Guggenheim
As previously reported, Guggenheim analyst Michael Schmidt downgraded Incyte (INCY) to Neutral from Buy, stating that he now views the shares as fairly valued following their strong performance in 2019. Schmidt also downgraded Seattle Genetics (SGEN) to Neutral from Buy, citing the same rationale. Among the companies expected to be commercial in 2020 that he covers, Schmidt maintains Buy ratings on Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC), Deciphera (DCPH), Exelixis (EXEL), Genmab (GMAB), and Immunomedics (IMMU).
12/12/19
DBAB
12/12/19
DOWNGRADE
Target $1570
DBAB
Hold
Genmab downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Richard Parkes downgraded Genmab (GMAB) to Hold from Buy with a DKK 1,570 price target. The analyst says the current valuation reflects the company's pipeline. AstraZeneca (AZN) and Roche (RHHBY) are his top large cap picks in European pharmaceuticals due to their "innovation advantage."
10/04/19
GUGG
10/04/19
NO CHANGE
GUGG
Guggenheim positively biased on Biotech heading into earnings
Guggenheim analysts Whitney Ijem, Etzer Darout, Yatin Suneja and Michael Schmidt offered a preview for their joint Biotech coverage ahead of the group's earnings reporting season. Biotech stocks continued their downward trend in the quarter amid negative market sentiment and the analysts think the bar for companies to raise 2019 guidance again may be a bit higher following increases in FY19 consensus estimates on the heels of strong Q2 earnings results. However, they are postively biased on the group and have confidence in FY19 guidance and estimates, the analysts said. They see Alexion (ALXN), Biogen (BIIB), Genmab (GMAB), GW Pharmaceuticals (GWPH), Incyte (INCY), Neurocrine (NBIX), Regeneron (REGN) and Seattle Genetics (SGEN) as well positioned relative to expectations, Ijem, Darout, Suneja and Schmidt tell investors.
01/13/20
RHCO
01/13/20
INITIATION
Target $28
RHCO
Buy
Genmab initiated with a Buy at SunTrust
SunTrust analyst Asthika Goonewardene initiated coverage of Genmab with a Buy rating and $28 price target. The analyst sees "substantial" potential for the company's two antibody drug conjugates in cancer treatment, with topline contributions in indications with evidence of tumor response at over DKK10B. Goonewardene further cites her expectations of Genmab retaining all rights until a partnership for its bispecific antibody GEN3013 in hematology is announced.
IDXG Interpace Biosciences
$0.62

(0.00%)

09/25/19
OPCO
09/25/19
INITIATION
Target $3
OPCO
Outperform
Interpace Diagnostics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Kevin DeGreeter initiated Interpace Diagnostics with an Overweight and $3 price target.
09/25/19
OPCO
09/25/19
INITIATION
Target $3
OPCO
Outperform
Oppenheimer starts Interpace at Outperform, sees 'clear path to BioPharma'
As previously reported, Oppenheimer analyst Kevin DeGreeter initiated Interpace Diagnostics with an Overweight rating and $3 price target, stating that he views it as an "emerging growth story in the oncology diagnostics space." The company recently entered a new high growth market with the acquisition of a BioPharma testing business, it continues to secure improved payor coverage for its ThyGeNEXT and ThyraMIR tests and it has a strategic investor that may support additional business development, the analyst stated.Target $3.
LCTX Lineage Cell Therapeutics
$0.75

-0.0146 (-1.92%)

PHIO Phio Pharmaceuticals
$0.20

0.0117 (6.35%)

PJC Piper Jaffray
$0.00

(0.00%)

10/04/19
BUCK
10/04/19
INITIATION
Target $80
BUCK
Neutral
Piper Jaffray initiated with a Neutral rating at Buckingham
Buckingham analyst James Mitchell initiated coverage of Piper Jaffray with a Neutral rating and $80 price target.
10/04/19
BUCK
10/04/19
INITIATION
Target $80
BUCK
Neutral
Piper Jaffray initiated with a Neutral at Buckingham
Buckingham analyst James Mitchell initiated coverage of Piper Jaffray with a Neutral rating and $80 price target. In a research note to investors, Mitchell says Piper Jaffray, soon to be Piper Sandler Cos, is a proven market share gainer with a long runway for consolidating the fragmented landscape for middle market financial advisory services. That said, he anticipates a better entry point forthcoming and view the stock's current valuation as fair given cyclical and execution-related risks.
TNXP Tonix Pharmaceuticals
$1.48

0.03 (2.07%)

08/30/19
ROTH
08/30/19
NO CHANGE
Target $1.3
ROTH
Buy
Tonix Pharmaceuticals price target lowered to $1.30 from $4 at Roth Capital
Roth Capital analyst Scott Henry lowered his price target for Tonix Pharmaceuticals to $1.30 from $4.00 while maintaining a Buy rating on the shares. While dilution from the company's equity offering in July was "painful," it should have enough cash runway into a data release, Henry tells investors in a research note.
04/18/19
ROTH
04/18/19
UPGRADE
ROTH
Buy
Tonix Pharmaceuticals upgraded to Buy from Neutral at Roth Capital
04/18/19
04/18/19
UPGRADE
Target $4

Buy
Tonix Pharmaceuticals upgraded to Buy at Roth Capital
As previously reported, Roth Capital analyst Scott Henry upgraded Tonix Pharmaceuticals to Buy from Neutral given that the company is attempting its third shot at the PTSD indication with the RECOVERY trial, enrollment adjustments give the trial a "reasonable shot at success," the cash runway could get the company to the key PTSD data readout in the first half of 2020, and the stock looks interesting using only a about 20% chance at approval. The analyst also raised his price target on the shares to $4 from 75c.
TROV Trovagene
$1.47

0.15 (11.41%)

03/01/19
MAXM
03/01/19
NO CHANGE
Target $8
MAXM
Buy
Trovagene price target lowered to $8 from $18 at Maxim
Maxim analyst Jason McCarthy lowered his post-split price target for Trovagene to $8 from $18, which reflects dilution associated with future capital raises. The analyst keeps a Buy rating on the shares ahead of a "busy" American Association for Cancer Research annual meeting for the company in late March. Trovagene now has three funded clinical trials with Onvansertib, and as updates are provided in 2019, they should, if positive, support a higher valuation, McCarthy tells investors in a research note.
VCYT Veracyte
$28.58

0.17 (0.60%)

07/31/19
LSCM
07/31/19
INITIATION
Target $35
LSCM
Buy
Veracyte initiated with a Buy at Lake Street
Lake Street analyst Thomas Flaten started Veracyte with a Buy rating and $35 price target. Veracyte can expand its offering to improve decision-making across the patient care continuum by leveraging its technology and bioinformatics platforms to develop and commercialize new product offerings, Flaten tells investors in a research note. He believes the company's late 2019 nasal swab test data for lung cancer "could further validate this evolution."
07/02/19
07/02/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Veru (VERU) initiated with an Overweight at Cantor Fitzgerald. 2. Uber (UBER) initiated with a Hold at Stifel. 3. Wyndham Hotels & Resorts (WH) initiated with an Overweight at Barclays. 4. Veracyte (VCYT) initiated with a Buy at Needham. 5. Paysign (PAYS) initiated with a Buy at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/04/19
LSCM
12/04/19
NO CHANGE
Target $35
LSCM
Buy
Veracyte answered key question with NanoString pact, says Lake Street
A central question about the long-term Veracyte (VCYT) growth story has been how to bridge the gap between its U.S., lab-based business and the much larger global market opportunity, Lake Street analyst Thomas Flaten tells investors in a research note. He believes the company provided a "compelling answer to that question" with the NanoString (NSTG) announcement. The analyst thinks the characteristics of the nCounter system will enable Veracyte to fully leverage the system in its bid to build a global presence. Flaten reiterates a Buy rating on the shares with a $35 price target.
07/31/19
07/31/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Verra Mobility (VRRM) initiated with a Neutral at Goldman Sachs. 2. Myomo (MYO) initiated with a Buy at Ascendiant. 3. Chiasma (CHMA) initiated with an Overweight at Piper Jaffray. 4. IAA (IAA) initiated with a Buy at Jefferies. 5. Veracyte (VCYT) initiated with a Buy at Lake Street. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
VIE Viela Bio
$37.10

4.17 (12.66%)

10/28/19
GUGG
10/28/19
INITIATION
Target $44
GUGG
Buy
Guggenheim starts Viela Bio at Buy, makes stock Best Idea
Guggenheim analyst Seamus Fernandez initiated coverage of Viela Bio with a Buy rating and $44 price target. The analyst makes the stock his Best Idea, seeing a potential path to a three-to-five times return over the next five years. Viela is a "uniquely compelling" biotech investment opportunity for several reasons, including a senior leadership team with deep biopharma roots, the unique spinout origin story from AstraZeneca (AZN), and large total addressable markets across various autoimmune diseases, Fernandez tells investors in a research note. With five biologic assets including inebilizumab already filed with the FDA, Viela "is well on its way to being a fully integrated biotechnology company focused on autoimmune disease," contends the analyst.
10/28/19
MSCO
10/28/19
INITIATION
Target $25
MSCO
Overweight
Viela Bio initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Jeffrey Hung initiated coverage of Viela Bio with an Overweight rating and $25 price target. Viela reported positive Phase 3 data for inebilizumab earlier this year in neuromyelitis optica spectrum disorder and he think the drug is likely to be approved by mid-2020 and become "one of the favored treatments" for NMOSD, though Hung added that it will be "an increasingly competitive market" as inebilizumab could be the second approved treatment for the rare autoimmune disorder. Viela is also developing inebilizumab in three additional indications, Hung noted.
10/28/19
GSCO
10/28/19
INITIATION
Target $32
GSCO
Buy
Viela Bio initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Paul Choi initiated coverage of Viela Bio with a Buy rating and $32 price target. The analyst likes the outlook for the company's lead asset, inebilizumab, which he expects to become the market leader in neuromyelitis optica spectrum disorder. Further, Viela has a "robust" autoimmune pipeline with opportunities to expand inebilizumab into areas of significant unmet medical need, says the analyst.
10/28/19
COWN
10/28/19
INITIATION
COWN
Outperform
Viela Bio initiated with an Outperform at Cowen
Cowen analyst Chris Shibutani initiated coverage of Viela Bio with an Outperform rating.
PSTV Plus Therapeutics
$2.81

0.02 (0.72%)

RDUS Radius Health
$20.14

1.77 (9.64%)

08/29/19
SBSH
08/29/19
UPGRADE
Target $40
SBSH
Buy
Radius Health upgraded to Buy from Neutral at Citi
Citi analyst Mohit Bansal upgraded Radius Health to Buy from Neutral and raised his price target for the shares to $40 from $24. The analyst's close look at the patch clinical trial indicates a "reasonable likelihood of success." Patch can at least double the market and could help Tymlos generate combined sales of $830M by 2028, Bansal tells investors in a research note. With patch and Elacestrant data expected in 2021, investors might start to get in the name later this year or early next year, says the analyst. He sees fair value for Radius Health shares of $54 to $100 if the patch works.
05/29/19
GSCO
05/29/19
UPGRADE
Target $38
GSCO
Buy
Radius Health upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Paul Choi upgraded Radius Health to Buy from Neutral after assuming coverage of the name. He raised his price target for the shares to $38 from $26. The analyst believes Tymlos will continue to gain share with the abaloparatide patch "expanding the market significantly." Further, elacestrant provides Radius "attractive optionality," Choi tells investors in a research note.
05/30/19
SBSH
05/30/19
INITIATION
Target $24
SBSH
Neutral
Radius Health assumed with a Neutral at Citi
Citi analyst Mohit Bansal assumed coverage of Radius Health with a Neutral rating and $24 price target. Under a prior analyst, Citi had a Neutral rating on the shares with a $22 price target.
11/06/19
LEER
11/06/19
NO CHANGE
Target $35
LEER
Outperform
Radius Health price target lowered to $35 from $49 at SVB Leerink
SVB Leerink analyst Geoffrey Porges lowered his price target for Radius Health to $35 from $49 following the company's quarterly results, saying that while the Tymlos market share gains remain on track with management guidance, the incremental value potential for other late stage development programs is fading with newly announced delays in the timing of the patch pivotal trial, and a formal decision to pivot away from oncology. Porges keeps an Outperform rating on the shares.
MRNA Moderna
$20.01

-0.21 (-1.04%)

01/10/20
ROTH
01/10/20
NO CHANGE
Target $24
ROTH
Buy
Moderna 'inching closer to a blockbuster CMV vaccine,' says Roth Capital
After Moderna reported additional Phase 1 data for its CMV mRNA vaccine, Roth Capital analyst Yasmeen Rahimi contended that the company is "inching closer to a blockbuster CMV vaccine" as the second interim readout confirms clean safety for mRNA-1647 with the neutralizing mAbs higher after a third dose. The analyst, who thinks interim safety and immunogenicity data due in the second half of this year can "serve as the green light for strategic interest in other mRNA vaccines," keeps a Buy rating on Moderna shares with a $24 price target.
12/03/19
BOFA
12/03/19
INITIATION
Target $29
BOFA
Buy
Moderna resumed with a Buy at BofA/Merrill
BofA/Merrill analyst Geoff Meacham resumed coverage of Moderna with a Buy rating and $29 price target. The analyst cites the company's phase 1 pipeline readouts having achieved a proof of concept with a "modified mRNA approach", showcasing "good tolerability, antigen-specific immune responses, and functional protein production." Meacham believes that Moderna's platform should de-risk further in 2020, with data-to-date supporting its potential to have broad therapeutic utility.
10/25/19
ROTH
10/25/19
INITIATION
Target $24
ROTH
Buy
Moderna initiated with a Buy at Roth Capital
Roth Capital analyst Yasmeen Rahimi initiated coverage of Moderna with a Buy rating and $24 price target. She believes the company is well funded to bring its 16 clinical programs to the next inflection point and sees a buying opportunity ahead of upcoming milestones, Rahimi tells investors. Investors, who "are challenged to find the needle in the haystack when it comes to picking the winning mRNA candidates from the 21 programs in development," continue to sit on the sidelines despite the company's continued clinical and preclinical progress, Rahimi added.
09/13/19
PIPR
09/13/19
NO CHANGE
Target $32
PIPR
Overweight
Moderna price target raised to $32 from $30 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Moderna to $32 from $30 after the company presented interim Phase I data on mRNA-1944 showing dose-dependent functional Chikingunya antibody production. These data have important read-through to Moderna's orphan disease pipeline, Tenthoff tells investors in a research note. He believes the company's pipeline is advancing and reiterates an Overweight rating on the shares.
MRK Merck
$89.93

0.5 (0.56%)

01/07/20
01/07/20
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pfizer (PFE) initiated with an Outperform at RBC Capital. 2. Boeing (BA) initiated with an Underperform at Longbow. 3. Merck (MRK) and AbbVie (ABBV) initiated with a Sector Perform at RBC Capital. 4. IVERIC bio (ISEE) initiated with an Outperform at Wedbush. 5. Kadant (KAI) initiated with a Neutral at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/18/19
MSCO
12/18/19
NO CHANGE
MSCO
Morgan Stanley upgrades Major Pharmaceuticals sector view to Attractive
Morgan Stanley analyst David Risinger upgraded his sector view on Major Pharmaceuticals to Attractive from In-Line. The analyst this morning also upgraded shares of Eli Lilly (LLY) to Overweight from Equal Weight with an increased price target of $150. His other Overweight-rated U.S. Major Pharma stock is Merck (MRK). The Pharma sector offers "strong growth and attractive valuations," Risinger tells investors in a research note. While admitting the 2020 political landscape needs to be watched closely, the analyst sees share drivers as being results relative to expectations, pipeline news flow, pricing developments, and election outcomes. Risinger expects most manufacturers to increase U.S. list prices in the mid-high single digit percentage range in 2020 and experience flattish net price inflation.
01/07/20
LEER
01/07/20
NO CHANGE
LEER
Outperform
OS miss in 1L SCLC 'a disappointing start to 2020' for Merck, says SVB Leerink
SVB Leerink analyst Daina Graybosch notes that Merck reported that Keytruda with platinum chemotherapy failed to meet the overall survival co-primary endpoint in the Phase 3, Keynote-604 study in newly-diagnosed, extensive-stage, small cell lung cancer. It did observe a significant improvement in progression free survival, but this alone is insufficient to support approval, the analyst argues. For Merck, frontline SCLC represented one of the largest metastatic market opportunities remaining for Keytruda to penetrate and Graybosch expects the stock could be down 1%-2% on the news. The failure adds more importance to the upcoming readout of Keynote-355 in 1L triple negative breast cancer, the analyst adds. Graybosch has an Outperform rating on the shares.
01/06/20
RBCM
01/06/20
INITIATION
Target $99
RBCM
Sector Perform
Merck initiated with a Sector Perform at RBC Capital
RBC Capital analyst Randall Stanicky initiated coverage of Merck with a Sector Perform rating and $99 price target, stating that while he believes it has a robust growth story based on the strength of Keytruda, he also believes that is "well understood."
NAVB Navidea
$1.49

-0.03 (-1.97%)

11/22/19
HCWC
11/22/19
INITIATION
Target $3
HCWC
Buy
Navidea initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Vernon Bernardino initiated coverage of Navidea Biopharmaceuticals with a Buy rating and $3 price target. The analyst believes believe the Manocept platform's clinical versatility is underappreciated. Manocept, the company's CD206-targeting technology platform, is a "backbone platform for creation of a pipeline of novel precision immunodiagnostic agents and immunotherapeutics," says the analyst. He believes Navidea shares offer an attractive value proposition.
07/11/19
MAXM
07/11/19
INITIATION
Target $2
MAXM
Buy
Navidea initiated with a Buy at Maxim
Maxim analyst Jason McCarthy started Navidea with a Buy rating and $2 price target.
07/11/19
07/11/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Microsoft (MSFT) initiated with an Outperform at Cowen. 2. Petrobras (PBR) initiated with a Buy at Goldman Sachs. 3. Navidea (NAVB) initiated with a Buy at Maxim. 4. Immunic (IMUX) initiated with a Buy at Chardan. 5. Target (TGT) was initiated with a Conviction Buy at Goldman Sachs, while Walmart (WMT), Home Depot (HD), Lowe's (LOW), and Costco (COST) were initiated with a Buy, and Bed Bath & Beyond (BBBY) was initiated with a Sell. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/11/19
MAXM
07/11/19
INITIATION
Target $2
MAXM
Buy
Navidea initiated with a Buy at Maxim
Maxim analyst Jason McCarthy initiated Navidea with a Buy rating and a price target of $2, saying the Tc99m-tilmanocept immunodiagnostic platform that the company is developing has the potential to change the diagnostic paradigm across several larger therapeutic areas, starting with rheumatoid arthritis, or RA. With a phase 2B trial in RA already underway, the analyst expects the focus to turn to the interim data expected in the second half of this year and the completion of the trial in 2020.
NBSE NeuBase Therapeutics
$6.31

-0.19 (-2.92%)

09/24/19
BTIG
09/24/19
INITIATION
Target $15
BTIG
Buy
NeuBase Therapeutics initiated with a Buy at BTIG
BTIG analyst Thomas Shrader started NeuBase Therapeutics with a Buy rating and $15 price target. Parts of the NeuBase platform as risk-mitigated and collectively contributing to a next-generation iteration of peptide nucleic acids, Shrader tells investors in a research note. He believes the company's novel PNA platform is "primed" to attract" impressive partners" that could provide non-dilutive capital.
11/20/19
OPCO
11/20/19
INITIATION
Target $14
OPCO
Outperform
NeuBase Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Hartaj Singh initiated coverage of NeuBase Therapeutics with an Outperform rating and $14 price target. The analyst believes the company has "solved for many technical limitations to first-generation antisense oligonucleotides" and is bullish on NeuBase's approach with lead molecules NT0100 for Huntington's disease and NT0200 for myotonic dystrophy.
10/29/19
HCWC
10/29/19
INITIATION
Target $14
HCWC
Buy
NeuBase Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of NeuBase Therapeutics with a Buy rating and $14 price target. The company's platform has broad applicability, since it utilizes peptide-nucleic acid constructs that can achieve what cannot be accomplished using standard antisense oligonucleotides, contends the analyst.
NVO Novo Nordisk
$59.62

0.66 (1.12%)

01/03/20
GUGG
01/03/20
DOWNGRADE
GUGG
Neutral
Novo Nordisk downgraded to Neutral from Buy at Guggenheim
Guggenheim downgraded Novo Nordisk to Neutral from Buy.
11/19/19
RHCO
11/19/19
NO CHANGE
Target $28
RHCO
Buy
Dicerna price target raised to $28 from $24 at SunTrust
SunTrust analyst Robyn Karnauskas raised her price target on Dicerna (DRNA) to $28 and kept her Buy rating, saying the company's collaboration with Novo Nordisk (NVO) on liver-related cardiometabolic disease candidates demonstrate its ability to participate in larger deals with upside optionality. The analyst believes that Dicerna can become a "larger platform play" over the long term, comparable to Ionis Pharma (IONS) and Alnylam (ALNY).
11/22/19
PART
11/22/19
DOWNGRADE
PART
Hold
Novo Nordisk downgraded to Hold from Buy at Pareto
Pareto analyst Johan Unnerus downgraded Novo Nordisk to Hold from Buy with a price target of 385 kroner.
01/03/20
GUGG
01/03/20
DOWNGRADE
GUGG
Neutral
Novo Nordisk downgraded to Neutral on continued insulin headwinds at Guggenheim
Guggenheim analyst Seamus Fernandez downgraded Novo Nordisk to Neutral from Buy, stating that his below-consensus estimates for sales and EPS in 2020 reflect increasing competition and payer pressure across the global insulin business. While his bullish stance on prospects for the semaglutide franchise are unchanged, his above-consensus estimates for Ozempic and Rybelsus already include Obesity, implying little room for upside, Fernandez tells investors. Additionally, the increasing concentration in diabetes and GLP-1 limits Novo's diversity and "returning Bio-Pharma to growth will be no small task," Fernandez contends.
NVS Novartis
$94.47

0.765 (0.82%)

01/06/20
JPMS
01/06/20
UPGRADE
Target $103
JPMS
Overweight
JPMorgan upgrades Sanofi to Overweight on 'unjustified' valuation gap
JPMorgan analyst Richard Vosser upgraded Sanofi (SNY) to Overweight from Neutral with a price target of EUR 103, up from EUR 81. Sanofi should start to close the valuation gap relative to peers in 2020, Vosser tells investors in a research note. The analyst believes the stock's current multiple of 12.6 times is "unjustified," especially when Novartis (NVS) trades on 14.3 times for a similar growth profile of 2.7%. He also also sees the potential for earnings upgrades driven by Dupixent.
12/18/19
HCWC
12/18/19
NO CHANGE
Target $4
HCWC
Buy
Aduro Biotech price target lowered to $4 from $7 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target for Aduro Biotech (ADRO) to $4 from $7 after the company announced Novartis' (NVS) decision to remove ADU-S100 from its portfolio. While acknowledging the announcement is perceived as an overall negative, the analyst notes that Novartis remains committed to targeting the pathway. As such, he has no expectation that the company is going to alter the terms of its partnership with Aduro. Pantginis keeps a Buy rating on Aduro Biotech.
12/16/19
12/16/19
NO CHANGE

Novartis ends development of fevipiprant in asthma after Phase III failure
Novartis announced topline results from its pivotal global Phase III LUSTER-11and LUSTER-22studies exploring the efficacy and safety of the investigational oral, once-daily, DP2receptor antagonist fevipiprant. The pooled analyses of the LUSTER trials did not meet the clinically relevant threshold for reduction in rate of moderate -to-severe exacerbation compared to placebo over a 52-week treatment period for either of the doses. The studies included patients who had inadequately controlled moderate-to-severe asthma despite receiving inhaled mid-to-high dose corticosteroids and at least one additional controller. The totality of these results do not support further development of fevipiprant in asthma, Novartis said in a statement. "While the results of the LUSTER studies with fevipiprant are disappointing, they meaningfully contribute to our understanding of the DP2pathway in asthma. We are incredibly grateful to all the patients, their families and the investigators who participated in the studies and contributed greatly to this research," said John Tsai, Head Global Drug Development and Chief Medical Officer, Novartis.
12/16/19
EVER
12/16/19
DOWNGRADE
Target $381
EVER
In Line
Evercore downgrades Regeneron on Eylea risk from Beovu
Evercore ISI analyst Joshua Schimmer downgraded Regeneron Pharmaceuticals (REGN) to In Line from Outperform with an unchanged price target of $381. Early feedback on Novartis' (NVS) Beovu is stronger than expected, which creates risk of erosion for Regeneron's Eylea in 2020 and 2021, Schimmer tells investors in a research note. He now believes Eylea's erosion will be faster than anticipated and "dominate investor dialogue as investors check with specialists."
OVID Ovid Therapeutics
$3.59

0.09 (2.57%)

09/04/19
RBCM
09/04/19
INITIATION
Target $12
RBCM
Outperform
Ovid Therapeutics initiated with an Outperform at RBC Capital
RBC Capital analyst Brian Abrahams initiated Ovid Therapeutics with an Outperform rating and a price target of $12. The analyst believes that the Street is "overlooking" the potential for success in the company's Angelman's Syndrome, which he believes could generate $280M in out-year revenues. Abrahabs further points to the "considerable upside opportunity" for Ovid Therapeutics' Fragile X Syndrome drug and its OV935 program in refractory epilepsies, which he sees creating a "compelling" risk-reward on the shares.
09/24/19
SBSH
09/24/19
NO CHANGE
Target $10
SBSH
Buy
Ovid Therapeutics price target raised to $10 from $8 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Ovid Therapeutics to $10 from $8 saying soticlestat's treatment effect appears durable, clinically significant, and "clearly active" in patients with high baseline seizure frequency. The analyst, who is not concerned with the two patients that showed variable improvements in seizure frequency, keeps a Buy rating on shares of Ovid Therapeutics.
03/10/19
PIPR
03/10/19
NO CHANGE
Target $14
PIPR
Overweight
Ovid Therapeutics price target lowered to $14 from $20 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren lowered his price target Ovid Therapeutics to $14 after the company reported Q4 results and provided an updated outlook for 2019. The analyst, however, believes Ovid's three programs could result in "significant upside" from current share levels. He keeps an Overweight rating on the shares.
09/23/19
PIPR
09/23/19
NO CHANGE
Target $14
PIPR
Overweight
Piper says Ovid shares reflect little value for 'exciting' soticlestat program
Greater reductions in seizure frequency are being observed on the Endymion OLE trial out to 48 weeks, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The analyst views today's interim data from Ovid Therapeutics as "exciting" and reminds investors that soticlestat is a potential first-in-class CH24H inhibitor for the treatment of developmental and epileptic encephalopathies. Previously, reductions in seizure frequency up to 45% were observed out to three months, but this morning we learned that some patients who are approaching a year of treatment in the Endymion OLE trial are achieving reductions of 80%-90%, says Van Buren. The analyst, who feels the "deepening" responses being observed with repeat treatment is "encouraging," thinks shares of Ovid Therapeutics reflect very little value for the soticlestat program. He keeps an Overweight rating on the stock with a $14 price target.
STI Merged to become TFC
$0.00

(0.00%)

11/20/19
JANY
11/20/19
DOWNGRADE
JANY
Neutral
SunTrust downgraded to Neutral from Buy at Janney Montgomery Scott
Janney Montgomery Scott analyst Christopher Marinac downgraded SunTrust (STI) to Neutral from Buy to match his rating on BB&T (BBT) after the latter's acquisition of the former was approved by the Federal Reserve. The merger is set to close on December 6. On BB&T, Marinac said he expects share repurchases to resume post-merger, that he sees a slight net interest margin reduction on a pro-forma basis following the merger and that he sees his fair value estimate of $58.00 for BB&T shares as supportive of a Neutral rating.
11/11/19
JANY
11/11/19
DOWNGRADE
JANY
Neutral
Janney Montgomery Scott downgrades BB&T to Neutral, says premium may 'flatten'
As previously reported, Janney Montgomery Scott analyst Christopher Marinac downgraded BB&T (BBT) to Neutral from Buy. He believes Friday's announcement that First Horizon Bank (FHN) has entered into an agreement to acquire 30 branches from SunTrust Bank (STI) signals regulatory approval in Q4 and that the BB&T-SunTrust merger will close by year-end, which he calls "a positive development long that we think investors were beginning to question." However, with the merger soon closing he thinks the stock premium for BB&T "might flatten," Marinac tells investors in a research note. He raised his fair value estimate for BB&T shares to $58.00 from $57.50, but said the level of upside expectation is lower than what would warrant a Buy rating on the stock.
12/09/19
RBCM
12/09/19
DOWNGRADE
Target $155
RBCM
Outperform
PNC Financial downgraded to Outperform from Top Pick at RBC Capital
RBC Capital analyst Gerard Cassidy downgraded PNC Financial (PNC) to Outperform from Top Pick with an unchanged $155 price target. The analyst notes that while the outlook for the stock remains "robust" and he still views the company as one of the top performing U.S. banks, he prefers Truist Financial Corporation as his new Top Pick rated bank stock given the opportunity offered by its recent merger combining BB&T (BBT) and SunTrust (STI).
10/08/19
JEFF
10/08/19
NO CHANGE
JEFF
Jefferies changes five bank ratings after looking into 2020, 2021
Jefferies analyst Ken Usdin upgraded BB&T (BBT), SunTrust Banks (STI) and Regions Financial (RF) to Buy from Hold from Hold while downgrading M&T Bank (MTB) and Zions Bancorp (ZION) to Hold from Buy. Looking to 2020 and 2021, banks face slowing earnings growth and "ongoing sentiment hurdles," Usdin tells investors in a research note. The analyst's base case assumes a stable economy, but he notes that "trade talk could tip it either way." Further, the 2020 election could weigh not only on valuation multiples, but also on earnings estimates based on the regulatory outlook, adds the analyst. He believes attractive dividend yields and a shift toward value stocks could help, but admits that earnings revisions are biased down with more rate cuts likely. Regions "has led the pack" in protecting its net interest margin for a tougher rates environment, while BB&T has less downside to estimates relative to peers and a faster earnings growth rate given benefits from the pending merger-of-equals with SunTrust, contends Usdin.
XON Intrexon
$7.20

0.46 (6.82%)

03/01/19
NORL
03/01/19
DOWNGRADE
Target $10
NORL
Market Perform
Intrexon downgraded to Market Perform from Outperform at Northland
Northland analyst Robert Breza downgraded Intrexon to Market Perform from Outperform after the company reported Q4 results and its auditors issued a going concern opinion. While management indicated that it is pursuing several strategic alternatives, he believes investors will take a wait and see attitude, Breza said. He lowered his price target on Intrexon shares to $10 from $17.
06/18/19
JMPS
06/18/19
NO CHANGE
Target $14
JMPS
Outperform
Surterra cannabinoid pact a positive for Intrexon, says JMP Securities
After Intrexon and privately-held Surterra Wellness announced an exclusive licensing agreement to advance Surterra's cannabinoid production using Intrexon's proprietary yeast fermentation platform, JMP Securities analyst Jason N. Butler said he sees the pact as a positive for Intrexon that supports the value that can be generated across its platforms and sectors. He keeps an Outperform rating and $14 price target on Intrexon shares.
SLRX Salarius Pharmaceuticals
$3.20

0.15 (4.92%)

VVUS VIVUS
$2.72

-0.01 (-0.37%)

SIVB SVB Financial
$253.42

-0.36 (-0.14%)

08/13/19
JPMS
08/13/19
NO CHANGE
Target $265
JPMS
Overweight
JPMorgan sees 'tremendous buying opportunity' into SVB Financial shares
JPMorgan analyst Steven Alexopoulos recently held investor meetings with SVB Financial CFO Dan Beck and found the tone of the meetings "very positive." The company is more positive than peer banks right now given the "significant actions" it has taken over the past two years to dampen its level of asset sensitivity combined with being the "dominant player" in banking the innovation industry, which is the fastest growing segment within the global economy, Alexopoulos tells investors in a research note titled "Meetings: A Tremendous Buying Opportunity With International Business a Hidden Asset; Overweight." The analyst recommends taking "full advantage of the opportunity" to buy SIV shares at the current valuation. Investors appear to be getting a "tremendous hidden asset in the form of its international operations today for free," says Alexopoulos. He keeps an Overweight rating on the shares with a $265 price target.
01/02/20
RHCO
01/02/20
NO CHANGE
RHCO
Buy
SunTrust raises price targets on select regional banks on improved margins
SunTrust analyst Jennifer Demba is raising her price targets on select regional bank stocks heading into 2020, reflecting the expectations of a benign interest rate environment with maintained interest rates along with a "slightly better" forecast for net interest margins and continued strong asset quality, in spite of the slower loan growth and lower refinancing related mortgage fees. The analyst raises her price target forecast on Zions (ZION) to $60 from $52, United Community Bank (UCBI) to $35 from $32, South State Corp (SSB) to $97 from $90, Synovus Financial (SNV) to $48 from $40, SVB Financial (SIVB) to $285 from $250, Pinnacle Financial Corp (PNFP) to $74 from $65; Bank OZK (OZK) to $32 from $29, Hancock Holding (HWC) to $47 from $42, FB Financial (FBK) to $46 from $43, Comerica (CMA) to $75 from $67, Cadence Bancorp (CADE) to $19 from $16, BOK Financial (BOKF) to $90 from $82, and Ameris (ABCB) to $50 from $47.
01/09/20
BOFA
01/09/20
NO CHANGE
Target $300
BOFA
Buy
SVB Financial named top pick for 2020 at BofA
BofA analyst Erika Najarian named SVB Financial as her top pick for 2020 and raised her price target to $300. While interest rate volatility has masked the strong underlying performance recently, Najarian tells investors in a research note that she expects shares to re-rate higher on the back of accelerating revenue growth and better reflect SVB's significantly superior growth profile and improved EPS resiliency.
01/09/20
BOFA
01/09/20
NO CHANGE
BOFA
Amazaon, Wix.com, & SVB Financial added to US 1 List at BofA
BofA added Amazon.com (AMZN), Wix.com (WIX), and SVB Financial (SIVB) to the US 1 List and removed Synovus (SNV), Dropbox (DBX), and IHS Markit (INFO).
VRML Vermillion
$0.79

-0.0453 (-5.39%)

12/16/19
12/16/19
NO CHANGE

Vermillion management to meet with William Blair
Group Luncheon Meeting with Management to be held in the New York area on December 16 at 12:30 pm hosted by William Blair.
VKTX Viking Therapeutics
$7.36

0.045 (0.62%)

07/15/19
OPCO
07/15/19
INITIATION
Target $12
OPCO
Outperform
Viking Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jay Olson initiated Viking Therapeutics with an Outperform rating and $12 price target, citing his view that the company has a validated approach to nonalcoholic steatohepatitis, or NASH. He estimates lead asset VK2809 can have total worldwide peak unadjusted sales of $2.2B and he sets a 35% probability of success for the drug.
06/25/19
STFL
06/25/19
INITIATION
Target $14
STFL
Buy
Viking Therapeutics initiated with a Buy at Stifel
Stifel analyst Derek Archila initiated Viking Therapeutics with a Buy rating and $14 price target, citing his belief that the IND for VK2809 will be accepted and his view that concerns around the drug's tolerability profile are unwarranted. He is confident that the FDA will allow Viking to initiate a Phase 2b study in biopsy proven non-alcoholic steatohepatitis patients, Archila tells investors.
06/25/19
STFL
06/25/19
INITIATION
Target $126
STFL
Hold
Madrigal Pharmaceuticals initiated with a Hold at Stifel
Stifel analyst Derek Archila initiated Madrigal Pharmaceuticals (MDGL) with a Hold rating and $126 price target, stating that he is positively biased heading into Phase 3 amid emerging evidence that point to the possibility resmetirom could demonstrate a benefit on fibrosis over time. However, he thinks the stock could be volatile around updates from competitors such as Viking Therapeutics (VKTX) and Genfit (GNFT) and sees few catalysts specific to Madrigal to drive shares up in the next 12-18 months, Archila tells investors.
11/21/19
RHCO
11/21/19
NO CHANGE
RHCO
Buy
Viking posting for VOYAGER includes 'nothing concerning,' says SunTrust
SunTrust analyst Joon Lee said he sees "nothing concerning" in the ClinicalTrials.gov posting for Viking Therapeutics' VOYAGER study, stating that the inclusion criteria is "minimally restrictive." He also heard some investors voice concern that the study may only be six months, but he spoke with the company's CEO, who confirmed it will be a 12 month study. The analyst, who thinks confusion about the study may have lead to share weakness in recent days, reiterates a Buy rating on Viking shares.

TODAY'S FREE FLY STORIES

JNJ

Johnson & Johnson

$149.03

0.78 (0.53%)

13:17
01/17/20
01/17
13:17
01/17/20
13:17
Periodicals
Judge cuts J&J punishment in Risperdal case to $6.8M from $8B, Bloomberg reports »

On October 8, 2019,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 09

    Mar

  • 17

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
01/17/20
01/17
13:17
01/17/20
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
01/17/20
01/17
13:16
01/17/20
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKR

Baker Hughes

$23.56

0.06 (0.26%)

13:04
01/17/20
01/17
13:04
01/17/20
13:04
Hot Stocks
Baker Hughes reports U.S. rig count up 15 to 796 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Mar

MDR

McDermott

$0.73

0.0119 (1.66%)

13:02
01/17/20
01/17
13:02
01/17/20
13:02
Hot Stocks
McDermott announces start of commercial operation of Freeport LNG Train 2 »

McDermott International,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$240.69

0.17 (0.07%)

13:02
01/17/20
01/17
13:02
01/17/20
13:02
Recommendations
Amgen analyst commentary  »

Amgen raised prices today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

BKR

Baker Hughes

$23.57

0.07 (0.30%)

13:01
01/17/20
01/17
13:01
01/17/20
13:01
Hot Stocks
Breaking Hot Stocks news story on Baker Hughes »

Baker Hughes reports U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Mar

SNCA

Seneca Biopharma

$3.09

1.84 (147.20%)

12:59
01/17/20
01/17
12:59
01/17/20
12:59
Hot Stocks
Seneca Biopharma surges after saying talks starting with 'interested parties' »

Shares of micro-cap…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUPH

Aurinia Pharmaceuticals

$20.02

0.19 (0.96%)

12:45
01/17/20
01/17
12:45
01/17/20
12:45
Options
Aurinia Pharmaceuticals call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
01/17/20
01/17
12:45
01/17/20
12:45
General news
Breaking General news story  »

Week of 1/17 Baker-Hughes…

12:45
01/17/20
01/17
12:45
01/17/20
12:45
General news
Breaking General news story  »

Week of 1/17 Baker-Hughes…

DLAKY

Lufthansa

$0.00

(0.00%)

12:41
01/17/20
01/17
12:41
01/17/20
12:41
Periodicals
Lufthansa extends Tehran flight halt until March 28, Reuters reports »

Lufthansa said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TM

Toyota

$139.71

-0.32 (-0.23%)

12:36
01/17/20
01/17
12:36
01/17/20
12:36
Hot Stocks
Toyota provides outline of production alignment through 2022 »

To "improve the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TM

Toyota

$139.71

-0.32 (-0.23%)

12:33
01/17/20
01/17
12:33
01/17/20
12:33
Hot Stocks
Toyota Indiana completes $1.3B modernization, adds 550 new jobs »

Toyota Indiana invested…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:30
01/17/20
01/17
12:30
01/17/20
12:30
General news
Treasury Dealer Agenda: the dealer meeting will be held on January 30, 31 »

Treasury Dealer Agenda:…

12:30
01/17/20
01/17
12:30
01/17/20
12:30
General news
Breaking General news story  »

Federal Reserve Board of…

12:30
01/17/20
01/17
12:30
01/17/20
12:30
General news
Breaking General news story  »

Federal Reserve Board of…

AXTA

Axalta Coating

$30.30

0.225 (0.75%)

12:25
01/17/20
01/17
12:25
01/17/20
12:25
Options
Axalta Coating call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

12:25
01/17/20
01/17
12:25
01/17/20
12:25
Conference/Events
Federal Reserve Board of Governors Vice Chairman speaks at a meeting »

Randal Quarles, Vice…

MSFT

Microsoft

$165.58

-0.66 (-0.40%)

, WORK

Slack Technologies

$22.68

-0.28 (-1.22%)

12:23
01/17/20
01/17
12:23
01/17/20
12:23
Periodicals
Microsoft to launch global ad campaign for Teams, CNBC reports »

Microsoft (MSFT) will…

MSFT

Microsoft

$165.58

-0.66 (-0.40%)

WORK

Slack Technologies

$22.68

-0.28 (-1.22%)

IPG

Interpublic Group

$23.96

0.22 (0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 12

    Feb

  • 25

    Feb

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
01/17/20
01/17
12:17
01/17/20
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
01/17/20
01/17
12:16
01/17/20
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$144.95

-0.15 (-0.10%)

12:07
01/17/20
01/17
12:07
01/17/20
12:07
Periodicals
Disney dropping 'Fox' name from 21st Century Fox assets, Variety reports »

Disney is dropping the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Feb

TWOU

2U

$22.88

1.09 (5.00%)

12:06
01/17/20
01/17
12:06
01/17/20
12:06
Periodicals
2U mulls potential sale after activist pressure, Bloomberg reports »

2U has tapped advisers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$315.89

0.56 (0.18%)

12:04
01/17/20
01/17
12:04
01/17/20
12:04
Hot Stocks
Apple announces overall deal with Julia Louis-Dreyfus for TV+ »

Apple has signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.